RIO DE JANEIRO, BRAZIL - The findings, so far, are extremely positive: the vaccine was able to boost production of the rare cells needed to generate antibodies against HIV in 97% of subjects. In phase 1 clinical trials, 48 healthy adult volunteers received either a placebo or two doses of the immunizer, along with an adjuvant developed by GlaxoSmithKline, a British pharmaceutical company.
The clinical trial was small, and the results have not yet been published in any scientific journal. Still, in phase 1, many more tests will have to be performed until the final vaccine is achieved. Even so, the . . .